Physician profile
Valeriya Klats
NPI 1134506678
$70,611.11
in general payments reported to CMS, 2019-2025
20 companies · $33K in 2025
The $33K reported for 2025 was more than what 98% of Pain Medicine (Psychiatry & Neurology) providers received nationally (typical 2025 total: $405).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2020: $57.06 · 2021: $1,097 · 2022: $795 · 2023: $20K · 2024: $15K · 2025: $33K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $60K · Consulting Fee: $4,925 · Food and Beverage: $3,102 · Travel and Lodging: $425 · Education: $36.48.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $60,174.00 |
| Consulting Fee | $4,925.00 |
| Food and Beverage | $3,102.23 |
| Travel and Lodging | $424.70 |
| Education | $36.48 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $42,775.74 | 2021-2025 | |
| Pfizer INC. | $25,826.44 | 2023-2025 | |
| Lundbeck LLC | $386.26 | 2021-2025 | Vyepti |
| Biohaven Pharmaceutical Holding Company Ltd. | $291.15 | 2022 | |
| Biohaven Pharmaceuticals, INC. | $259.23 | 2021 | |
| Lilly USA, LLC | $237.36 | 2021-2022 | |
| Allergan, INC. | $143.25 | 2020-2022 | |
| Novo Nordisk INC | $125.00 | 2025 | Wegovy |
| Teva Pharmaceuticals USA, INC. | $89.72 | 2021 | |
| Impel Pharmaceuticals INC. | $73.90 | 2023 | Trudhesa |
| Neurocrine Biosciences, INC. | $70.99 | 2021 | |
| Amgen INC. | $66.41 | 2020-2022 | |
| Adamas Pharmaceuticals, INC. | $63.23 | 2020-2021 | |
| Amneal Pharmaceuticals LLC | $59.00 | 2021 | |
| Sunovion Pharmaceuticals INC. | $43.70 | 2021 |
Show all 20 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Upsher-Smith Laboratories LLC | $33.20 | 2022-2023 | |
| Merz Pharmaceuticals, LLC | $19.41 | 2021 | |
| Alexion Pharmaceuticals, INC. | $17.42 | 2025 | Ultomiris |
| Currax Pharmaceuticals LLC | $15.81 | 2021 | |
| Mdd US Operations, LLC | $13.89 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Valeriya Klats listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.